Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-03 03:22:46 - browse：9

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What to expect at HLTH 2023, the health care industry conference

leisure time

WSS

U.K. Biobank has 500,000 peoples' genome sequences available

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Organ aging and disease risk measured by new blood test

Why Charlie Gard's case is so disturbing to Americans

Disappointing trial forces Pfizer to pivot on obesity medicine plans

How to pay for weight loss drugs and save Medicare

focus

Wikipedia

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

30 years of 'Listening to Prozac'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Rep. Raul Ruiz on the physician shortage and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What to expect at HLTH 2023, the health care industry conference

The high cost of giving birth even with insurance

ReNAgade cuts staff seven months after raising $300 million

New air purifier tech could be key to improving indoor air quality

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

focus

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

30 years of 'Listening to Prozac'

With clinical trial data readouts, here's how to spot spin

Diagnostic tests are hitting their mathematical limits

Analysis of telehealth claims data suggest service duplication

Mayo Clinic plans $5B tech

leisure time

leisure time

focus

Wikipedia